Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Why this document exists A medicine can be approved by regulators and still fail commercially, because the public bodies and insurers who pay for medicines apply their own, separate test.
Overview Between February and June 2026, twelve drugs previously rated by MARA received new regulatory approvals — from the FDA or EMA — triggering a formal surveillance reassessment of each
Overview MARA Rating completed 17 new Reimbursement Risk Assessments in June 2026. The assets span nine therapeutic areas: oncology, obesity, neurology, rare disease, pulmonology, cardiology, immunology, hepatology, and infectious disease.
MARA Rating — Back-test series, June 2026 We built MARA to answer one question before the decision arrives: given this evidence profile, how have HTA bodies historically responded to assets
Learn how MARA Rating’s Uncertainty & Sensitivity domain (A++–C) predicts HTA outcomes; why 2.6 vs 2.0 scores sway payer trust, pricing & reimbursement. Since 2020, we’ve seen a clear split:
How Evidence Quality Scores Impact HTA Assessment Success: The 2.9 Benchmark Since 2020, assets with an average Evidence Quality score of 2.9 have sailed through HTA assessments more regularly than
Many breakthrough therapies in the U.S. stumble in their first year on the market, despite strong clinical promise. The reason isn’t usually safety or efficacy. It’s cost pressures, evidence maturity, and system
About MARA Rating: We provide an independent Market‑Access Risk Assessment (A++ → C) built on a transparent, 10‑domain HTA framework. Use the score to benchmark an asset’s access prospects against
MARA Rating Insight: Why Resource Use & Cost Implications Decide Coverage Since 2020, one pattern has been clear in our database: Assets averaging 2.8 in Resource Use & Cost progressed through HTA
MARA Rating’s Care Pathway Integration score (A++–C) predicts HTA endorsement and payer adoption by measuring clinical guideline alignment, workflow efficiency, administration ease, and implementation feasibility. Too often, M&A teams under-weight